Please select the outcome measures that correspond to the clinical trial below.
Title: Intranasal Oxytocin in the Treatment of Autism
Brief Summary: The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.


Options:
A: Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score (Week 8)
B: Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs (From Screening (up to 42 days prior to treatment start) through Week 52 (end of study) for SAEs; from Week 0 (Baseline) through Week 52 (End of Study) for AEs); Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52 (Baseline, Week 8, Week 26, Week 52); Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52 (Baseline, Week 8, Week 26, Week 52); Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint (Baseline, Week 8, Week 26, Week 52); Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities (At screening (up to 42 days prior to treatment start), Week 8, Week 26, Week 52); Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities (At screening (up to 42 days prior to treatment start), Week 8, Week 26, Week 52); Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities (At screening (up to 42 days prior to treatment start), Week 8, Week 26, Week 52); Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities (At screening (up to 42 days prior to treatment start), Week 8, Week 26, Week 52); Number of Potentially Clinically Relevant Vital Sign Abnormalities (At screening (up to 42 days prior to treatment start), Week 0 (Baseline), Week 1, Week 2, Week 4, Week 8, Week 14, Week 20, Week 26, Week 34, Week 42, Week 52 (Endpoint)); Mean Change From Baseline in Patient Weight (At screening (up to 42 days prior to treatment start), Week 0 (Baseline), Week 1, Week 2, Week 4, Week 8, Week 14, Week 20, Week 26, Week 34, Week 42, Week 52 (Endpoint)); Mean Change From Baseline by Time Period in Body Weight Z-Score (At screening (up to 42 days prior to treatment start), Week 0 (Baseline), Week 1, Week 2, Week 4, Week 8, Week 14, Week 20, Week 26, Week 34, Week 42, Week 52 (Endpoint)); Mean Change From Baseline in Patient Body Mass Index (BMI) (At screening (up to 42 days prior to treatment start), Week 0 (Baseline), Week 1, Week 2, Week 4, Week 8, Week 14, Week 20, Week 26, Week 34, Week 42, Week 52 (Endpoint)); Mean Change From Baseline By Time Period in BMI Z-Score (At screening (up to 42 days prior to treatment start), Week 0 (Baseline), Week 1, Week 2, Week 4, Week 8, Week 14, Week 20, Week 26, Week 34, Week 42, Week 52 (Endpoint))
C: Clinical Global Impressions Scale - Improvement - Social (6 Weeks); Repetitive Behavior Scale - Revised (6 Weeks); Diagnostic Analysis of Nonverbal Accuracy, Paralanguage Test (6 Weeks)
D: Clinical Global Impression-Improvement Scale (CGI-I) (Baseline to 12 weeks)

Answer: C